Research programme: BACE1 protein inhibitors - Merck and Co

Alternative Names: SCH-1359113; SCH-1682496; SCH-785532

Latest Information Update: 04 Nov 2017

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Merck & Co; Sunesis Pharmaceuticals
Developer Merck & Co
Class Guanidines; Hydantoins; Macrocyclic compounds; Piperidines; Pyrimidinones; Small molecules; Sulfones
Mechanism of Action BACE1 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

No development reported Alzheimer's disease

Most Recent Events

04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (PO)
10 Apr 2008 Research phase development is ongoing
21 Jul 2006 Data presented at the 10th International Conference on Alzheimer's Disease and Related Disorders (ICAD-2006) have been added to the Alzheimer's Disease pharmacodynamics section

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.